化疗栓塞作为一线治疗用于门静脉段支受侵且肿瘤负荷限于单肝段的肝细胞癌
回顾性分析192例以化疗栓塞为一线治疗的肝细胞癌伴门静脉癌栓局限于单肝段患者,中位总生存期33个月,1、3、5年生存率分别为86%、48%、39%,主要并发症率5%;多因素分析发现浸润型肝癌、超出up-to-11标准、Child-Pugh B级和血清AFP≥400 ng/mL与生存显著相关。
要点
- 化疗栓塞治疗单肝段门静脉癌栓的肝细胞癌,中位OS 33个月,5年OS率39%。
- 主要并发症率5%,1个月完全缓解率35%、部分缓解率47%。
- 浸润型肝癌、超出up-to-11标准、Child-Pugh B级、AFP≥400 ng/mL与生存显著相关。
核心结论
- 化疗栓塞在门静脉癌栓局限于单肝段的肝细胞癌中显示出较高的安全性和有效性,有助于改善生存;四个治疗前危险因素与化疗栓塞后生存率显著相关。
研究设计与样本
- 回顾性分析2008年3月至2023年1月期间接受化疗栓塞作为一线治疗的192例初治局部晚期肝细胞癌伴门静脉癌栓局限于单肝段的患者,采用Cox回归分析总生存期及治疗前危险因素,并评估并发症、影像学肿瘤反应和无进展生存期。
诊断标准与关键数值
- 化疗栓塞后1、3、5年总生存率分别为86%、48%、39%,中位总生存期33个月。
- 多因素分析显示浸润型肝癌(P=0.02;HR 1.60)、超出up-to-11标准(P=0.002;HR 2.26)、Child-Pugh B级(P=0.01;HR 2.35)、血清AFP≥400 ng/mL(P=0.01;HR 1.69)为显著的治疗前危险因素。
- 化疗栓塞后1个月,35%患者达到完全缓解,47%达到部分缓解,11%疾病稳定,7%疾病进展。
- 化疗栓塞后中位无进展生存期为12个月,主要并发症率为5%。
临床应用与阅片要点
- 对于门静脉癌栓局限于单肝段且肿瘤负荷有限的肝细胞癌患者,化疗栓塞可作为一线治疗选择。
- 治疗前应评估浸润型肝癌、up-to-11标准、Child-Pugh分级和血清AFP水平,以识别生存预后较差的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the safety and effectiveness of chemoembolization for hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT) confined to a monosegment of the liver.
METHODS: A total of 192 treatment-naive patients who received chemoembolization between March 2008 and January 2023 as a first-line treatment for locally advanced HCC with PVTT limited to a monosegment were retrospectively analysed. Overall survival (OS) and the identification of pretreatment risk factors related to OS were investigated using Cox regression analysis. Complications, radiologic tumour response, and progression-free survival (PFS) following chemoembolization were investigated.
RESULTS: After chemoembolization, the 1-, 3-, and 5-year OS rates were 86%, 48%, and 39%, respectively, and the median OS was 33 months. Multivariable analyses revealed four significant pretreatment risk factors: infiltrative HCC (P = .02; HR, 1.60), beyond the up-to-11 criteria (P = .002; HR, 2.26), Child-Pugh class B (P = .01; HR, 2.35), and serum AFP ≥400 ng/mL (P = .01; HR, 1.69). The major complication rate was 5%. Of the 192 patients, 1 month after chemoembolization, 35% achieved a complete response, 47% achieved a partial response, 11% had stable disease, and 7% showed progressive disease. The median PFS after chemoembolization was 12 months.
CONCLUSIONS: Chemoembolization shows high safety and efficiency, and contributes to improved survival in patients with HCC with PVTT confined to a monosegment. Four risk factors were found to be significantly associated with improved survival rates after chemoembolization in patients with HCC with PVTT confined to a monosegment.
ADVANCES IN KNOWLEDGE: (1) Although systemic therapy with a combination of atezolizumab and bevacizumab (Atezo-Bev) is recommended as the first-line treatment when HCC invades the portal vein, chemoembolization is not infrequently performed in HCC cases in which tumour burden is limited. (2) Our study cohort (n=192) had a median OS of 33 months and a 5% major complication rate following chemoembolization, findings in the range of candidates typically accepted as ideal for chemoembolization. Thus, patients with HCC with PVTT confined to a monosegment may be good candidates for first-line chemoembolization.
引用
- Hwang H, Kim JH, Ko E, et al. Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level. Br J Radiol. 2024. PMID: 38445658. doi:10.1093/bjr/tqae052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。